Home monitoring for kidney transplant patients using finger-prick blood samples
Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples
This study is testing if kidney transplant patients can safely monitor their health at home using finger-prick blood samples instead of going to the doctor for check-ups.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT04369612 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of home-based monitoring for kidney transplant recipients by allowing them to take capillary blood samples via finger-prick and send them for laboratory analysis. Participants will be randomized to either standard follow-up care or home-based monitoring, where they will receive telephonic follow-ups from their transplant physician. The aim is to determine if this approach can maintain patient safety and reduce the need for in-person visits without increasing the risk of acute rejection episodes. The study will follow patients for 7-8 weeks post-transplant.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have received a kidney-only transplant and are on standard immunosuppressive therapy without specific antibodies.
Not a fit: Patients who are pregnant, breastfeeding, or experiencing ongoing acute rejection episodes will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance patient convenience and reduce hospital visits while maintaining effective monitoring of kidney transplant health.
How similar studies have performed: Similar studies have shown promise in home-based monitoring approaches, suggesting potential for success in this novel application for kidney transplant patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Kidney only transplant * Immunosuppressive therapy With at least one of; tacrolimus, cyclosporine, everolimus, sirolimus, mycophenolate * Standard immunological risk; no DSA, no PRA, not ABO-incompatible transplant * Age above 18 years * Followed at Oslo University Hospital-Rikshospitalet transplant center * Written informed consent Exclusion Criteria: * Pregnant or breast feeding female recipients * Ongoing acute rejection episodes at time of inclusion
Where this trial is running
Oslo
- Oslo Univeristy Hospital - Rikshospitralet — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Karsten Midtvedt, MD, PhD — Oslo University Hospital
- Study coordinator: Karsten Midtvedt, MD, PhD
- Email: kmidtved@ous-hf.no
- Phone: 0047-23071894
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.